Related Experiment Video
Updated: Aug 15, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1)
Susan W Barnett1, Indresh K Srivastava, Jeffrey B Ulmer
1Vaccines Research Department, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA. susan_barnett@chiron.com
Abstract:
The urgent need for a vaccine against HIV/AIDS requires that multiple strategies be employed and evaluated in a clinical setting. V2-loop deleted trimeric envelope (Env) immunogens (protein and DNA) from subtypes B and C human immunodeficiency virus type 1 (HIV-1) strains were produced for ongoing and future clinical evaluations with other HIV antigens, adjuvants and deliveries.
More Related Videos
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019